Homology Medicines, Inc.
Symbol: 0T6G.L
LSE
21.56
USDMarket price today
-0.7390
P/E Ratio
-0.0083
PEG Ratio
283.62M
MRK Cap
- 0.00%
DIV Yield
Homology Medicines, Inc. (0T6G-L) Financial Statements
Balance Sheet
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 82.7 | 175 | 155.9 | ||||||||
balance-sheet.row.short-term-investments | 0 | 43.4 | 141 | 47.5 | ||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.other-current-assets | 0 | 1.3 | 6 | 36 | ||||||||
balance-sheet.row.total-current-assets | 0 | 83.9 | 181 | 191.9 | ||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0.7 | 21.6 | 17.9 | ||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 25.8 | 2 | ||||||||
balance-sheet.row.tax-assets | 0 | 221.6 | 0 | 0 | ||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-non-current-assets | 0 | 222.2 | 47.5 | 19.8 | ||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-assets | 0 | 306.1 | 228.5 | 211.7 | ||||||||
balance-sheet.row.account-payables | 0 | 3.2 | 1.1 | 2.4 | ||||||||
balance-sheet.row.short-term-debt | 0 | 1.3 | 1.6 | 0.2 | ||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.long-term-debt-total | 0 | 49.4 | 11.9 | 5 | ||||||||
Deferred Revenue Non Current | 0 | -104.4 | 0 | 1.2 | ||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||
balance-sheet.row.other-current-liab | 0 | 7 | 18.7 | 11.4 | ||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 221.6 | 27.9 | 24.8 | ||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.capital-lease-obligations | 0 | 6.8 | 27.9 | 23.7 | ||||||||
balance-sheet.row.total-liab | 0 | 233.1 | 50.5 | 42.1 | ||||||||
balance-sheet.row.preferred-stock | 0 | 111.4 | 111.4 | 111.4 | ||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.retained-earnings | 0 | -542.1 | -429.1 | -424.1 | ||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | -0.4 | 0 | ||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 503.6 | 496.1 | 482.3 | ||||||||
balance-sheet.row.total-stockholders-equity | 0 | 73 | 178 | 169.7 | ||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 306.1 | 228.5 | 211.7 | ||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-equity | 0 | 73 | 178 | 169.7 | ||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||
Total Investments | 0 | 43.4 | 166.9 | 49.4 | ||||||||
balance-sheet.row.total-debt | 0 | 1.3 | 29.5 | 23.9 | ||||||||
balance-sheet.row.net-debt | 0 | -37.9 | -4.5 | -84.4 |
Cash Flow Statement
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -113 | -5 | -95.8 | ||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0.6 | 2.6 | 9.5 | ||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -19.2 | -38.8 | ||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 13.1 | 17.2 | ||||||||
cash-flows.row.change-in-working-capital | 0 | -7.2 | 3.4 | -41.8 | ||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.account-payables | 0 | 2.1 | -1 | -2.5 | ||||||||
cash-flows.row.other-working-capital | 0 | -9.3 | 4.3 | -39.3 | ||||||||
cash-flows.row.other-non-cash-items | 0 | 23.4 | -108.4 | 39.8 | ||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -0.2 | -1.3 | -2.4 | ||||||||
cash-flows.row.acquisitions-net | 0 | 0.6 | 130 | 48.4 | ||||||||
cash-flows.row.purchases-of-investments | 0 | -73.2 | -157.5 | -97.4 | ||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 174.2 | 65.5 | 49 | ||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -48.4 | ||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 101.3 | 36.7 | -50.8 | ||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.common-stock-issued | 0 | 0.2 | 0.6 | 52.2 | ||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0.6 | 52.2 | ||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0.2 | 0.6 | 52.2 | ||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.net-change-in-cash | 0 | 5.3 | -74.4 | -109 | ||||||||
cash-flows.row.cash-at-end-of-period | 0 | 39.3 | 34 | 108.4 | ||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 34 | 108.4 | 217.4 | ||||||||
cash-flows.row.operating-cash-flow | 0 | -96.2 | -113.7 | -109.8 | ||||||||
cash-flows.row.capital-expenditure | 0 | -0.2 | -1.3 | -2.4 | ||||||||
cash-flows.row.free-cash-flow | 0 | -96.5 | -114.9 | -112.1 |
Income Statement Row
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1.2 | 3.2 | 34 | ||||||||
income-statement-row.row.cost-of-revenue | 0 | 0.6 | 2.6 | 9.5 | ||||||||
income-statement-row.row.gross-profit | 0 | 0.6 | 0.6 | 24.4 | ||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.operating-expenses | 0 | 92.7 | 133.9 | 120.4 | ||||||||
income-statement-row.row.cost-and-expenses | 0 | 93.3 | 136.5 | 129.9 | ||||||||
income-statement-row.row.interest-income | 0 | 5.6 | 3.2 | 0.2 | ||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 5 | 134.5 | 0.2 | ||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.total-operating-expenses | 0 | 5 | 134.5 | 0.2 | ||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0.6 | 2.6 | 9.5 | ||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||
income-statement-row.row.operating-income | 0 | -92.1 | -133.3 | -95.9 | ||||||||
income-statement-row.row.income-before-tax | 0 | -87.1 | 1.2 | -95.8 | ||||||||
income-statement-row.row.income-tax-expense | 0 | 0.3 | 0.7 | 0.5 | ||||||||
income-statement-row.row.net-income | 0 | -113 | -5 | -95.8 |
Frequently Asked Question
What is Homology Medicines, Inc. (0T6G.L) total assets?
Homology Medicines, Inc. (0T6G.L) total assets is 306119000.000.
What is enterprise annual revenue?
The annual revenue is N/A.
What is firm profit margin?
Firm profit margin is 2.827.
What is company free cash flow?
The free cash flow is -22.864.
What is enterprise net profit margin?
The net profit margin is 8.364.
What is firm total revenue?
The total revenue is 6.819.
What is Homology Medicines, Inc. (0T6G.L) net profit (net income)?
The net profit (net income) is -112961000.000.
What is firm total debt?
The total debt is 1318000.000.
What is operating expences number?
The operating expences are 92680000.000.
What is company cash figure?
Enretprise cash is 0.000.